Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Published Research Data Quantified findings from peer-reviewed studies on CJC-1295 amino acid residues in the CJC-1295 peptide sequence HPLC-verified purity range across published batch testing Published Research Studies on CJC-1295 2008 Growth hormone-releasing hormone analogues: chemistry and pharmacology Endocrine 2006 Prolonged stimulation of growth hormone secretion by CJC-1295 J Clin Endocrinol Metab Clinical study demonstrating CJC-1295's ability to produce sustained, dose-dependent increases in growth hormone and IGF-1 levels
The medicine has progressed through Phase 2 clinical trials , where participants achieved: Dose-dependent weight loss of up to 24.2% after 48 weeks at higher doses 83% of participants at the maximum 12 mg dose losing 15% or more of their body weight All patients taking 8 mg or above are achieving at least 5% weight loss Larger Phase 3 trials are now underway to confirm these findings in broader, more diverse patient groups and to build longer-term safety data
Common side effects of semaglutide include: 1 Nausea Abdominal pain Dizziness Stomach flu Diarrhea Headache Bloating Heartburn Vomiting Fatigue Belching Runny nose or sore throat Constipation Gas *All medications, including semaglutide, can cause side effects that can be mild or serious
Both are FDA-approved weekly injectable weight loss medications
